Zhao Min
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, West China Hospital, Sichuan University / West China School of Nursing, Sichuan University, Chengdu 610041, China.
Author ProfileShuai Wen
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, West China Hospital, Sichuan University / West China School of Nursing, Sichuan University, Chengdu 610041, China.
Author ProfileWang Aoxue
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, West China Hospital, Sichuan University / West China School of Nursing, Sichuan University, Chengdu 610041, China.
Author ProfileWang Guan
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, West China Hospital, Sichuan University / West China School of Nursing, Sichuan University, Chengdu 610041, China.
Corresponding Author:[email protected]
Author ProfileLiang Ouyang
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, West China Hospital, Sichuan University / West China School of Nursing, Sichuan University, Chengdu 610041, China.
Author ProfileAbstract
Tyrosine phosphorylation of intracellular proteins is a kind of
post-translational modification that regulates the signal transduction
in cellular process. The dephosphorylation of protein tyrosine
phosphatases (PTPs) on signal transduction proteins contributed their
role as a convergent node to mediate cross-talk between signaling
pathways. In cancer, PTPs-mediated pathways served as signaling hubs
through which cancer cells alleviated stress following the clinical
therapy, via promoting constitutive activation of growth-stimulatory
signaling pathways or influencing the immune-suppressive tumor
microenvironment. Preclinical evidences suggested that anticancer drugs
will release their greatest therapeutic potency when combined with PTP
inhibitors, reversing drug resistance that was responsible for clinical
failures during cancer therapy. Here, this review elaborated recent
insights that substantiated the role of PTPs-mediated pathways in
resistance to targeted cancer therapy and immune-checkpoint therapy,
leading to the proposal of targeting PTPs inhibition in anticancer
combination therapy for long-term disease regression. Clinical trials
have been initiated to evaluate the safety and efficacy of combination
therapy in advanced-stage tumors.